Pharmaceutical Technology· GlobalData Healthcare·· 2 小时前AI 评分13
ESMO26：Sac-TMT 在复发性子宫内膜癌中树立生存获益标杆
ESMO26: Sac-TMT sets survival benchmark in recurrent endometrial cancer
AI 导读
ESMO26 会议上，Sac-TMT 在复发性子宫内膜癌中树立生存获益标杆。该结论来自本次会议公布的相关研究数据。
正文 · 原文
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here
Powered by
来源：Pharmaceutical Technology · pharmaceutical-technology.com